Press Releases

Novan Announces Promising Results of SB204 Clinical Study

May 30, 2013

DURHAM, N.C. – Novan Therapeutics, today announced results from a recent clinical trial demonstrating that nitric oxide releasing drug candidate SB204 reduces colonization of the acne causing bacteria Propionibacterium acnes (P. acnes) in the skin of healthy volunteers.

Full Story

Novan Raises $11M; Acne Drug Heads for Clinical Trial

March 6, 2013

DURHAM, N.C. — Novan Therapeutics has closed on $11 million in financing as the company heads into clinical trials studying a potential new acne treatment.

Full Story

Novan’s SB204 Could Be First Topical Sebum Inhibitor

February 28, 2013

DURHAM, N.C. – Novan Therapeutics, a clinical-stage drug development company, today announced in vitro and animal testing data indicating that the company’s drug candidate, SB204, could lead to a topical treatment to reduce oil production in the skin.

Full Story

Close
Close